

## MATERIALS LICENSE

Amendment No. 07

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| Licensee   |   |
|--|---|
| 1. Marian Health Center  | In accordance with application dated January 15, 1985   |
| 2. 801 Fifth Street<br>Sioux City, IA 51101  | 3. License number 14-10222-02 is amended in its entirety to read as follows:                    |
|  | 4. Expiration date August 31, 1990  |
|  | 5. Docket or Reference No. 030-13901  |
| 6. Byproduct, source, and/or special nuclear material  | 7. Chemical and/or physical form  |
| A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 |
| B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35       | B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35                      |
| C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35        | C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35        |
| D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35         | D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35         |
| E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35        | E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35              |
|  | 8. Maximum amount that licensee may possess at any one time under this license                  |
|  | A. As necessary for uses authorized in Subitem 9.A  |
|  | B. 2 curies of each byproduct material authorized in Subitem 6.B                                |
|  | C. As necessary for uses authorized in Subitem 9.C  |
|  | D. As necessary for uses authorized in Subitem 9.D  |
|  | E. 1.5 curies total for all sources authorized in Subitem 6.E                                   |

8509170290 850814  
REG3 LIC30  
14-10222-02 PDR

1430 BL AUG 14 1985 COPY 2

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

14-10222-02

Docket or Reference number

030-13901

Amendment No. 07

6. Byproduct, source,  
and/or special nuclear  
material

7. Chemical and/or  
physical form

8. Maximum amount that  
licensee may possess  
at any one time  
under this license

F. Xenon-133

F. Gas or gas in solution  
that is the subject  
of an active (i.e., not  
withdrawn or terminated)  
"New Drug Application"  
(NDA) approved by FDA or  
an active (i.e., not  
withdrawn, terminated  
or on "clinical hold")  
"Notice of Claimed  
Investigational Exemption  
for a New Drug" (IND)  
that has been accepted  
by FDA

F. 100 millicuries

G. Uranium (Depleted in  
Uranium 235)

G. Cadmium plated metal

G. 160 kilograms

9. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

F. Blood flow studies. Pulmonary function studies.

G. To be used as shielding in linear accelerator.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 801 Fifth Street, Sioux City, Iowa.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

COPY

**MATERIALS LICENSE**  
SUPPLEMENTARY SHEET

License number

14-10222-02

Docket or Reference number

030-13901

Amendment No. 07

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

G. R. Skorey, M.D.

Groups I, II, III, IV, V and VI  
Xenon-133

D. C. Schenk, M.D.

Groups I, II and III  
Xenon-133

T. A. Ware, M.D.

Groups I, II, III, IV, V and VI  
Xenon-133

J. H. Washburn, M.D.

Group VI

David K. Brewer, M.D.

Groups I, II and III  
Xenon-133

Fahima Qalbani, M.D.

Groups I, II and III  
Xenon-133  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction

13. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

- Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
- Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
- Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem (a) above and of the license(s) specified in Subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under Subitem (a) above.

14. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
15. Patients containing Cobalt 60, Cesium 137 or Iridium 192 implants shall remain hospitalized until a source count and surveys made with an appropriate radiation detection instrument indicate that all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Commission for five (5) years from the time the implants are removed.

COPY

**MATERIALS LICENSE**  
SUPPLEMENTARY SHEET

License number

14-10222-02

Docket or Reference number

030-13901

Amendment No. 07

16. Patients containing Iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.
17. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
  - A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
  - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
  - C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.
18. The licensee shall follow the procedures contained in Appendix F, "Procedures for Safely Opening Packages Containing Radioactive Material" of Regulatory Guide 10.8, October 1980.
19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated January 15, 1985; letter dated August 4, 1985; and Model ALARA Program as contained in Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed

By James Mullauer

Materials Licensing Section, Region III

Date August 14, 1985

COPY